Table 5.
Research progress of existing natural compounds in angiogenesis in lung cancer.
| Natural compounds | ↓Signaling pathway | ↓Angiogenesis indication |
|---|---|---|
| Pristimerin (81) | Shh/Gli VEGF/VEGFR-2 |
Shh, Gli, ERK, AKT VEGF, CD31 |
| FP08S2 (82) | VEGFR2/ERK/VEGF | HIF-1α, VEGF |
| Terrein (83) | PI3K/AKT/mTOR MEK/ERK |
PI3K, AKT, mTORC1, p70S6K HIF-1α, VEGF, MMP-2, MMP-9 |
| FGA (84) | Integrin/AKT/mTOR | angiogenesis, cell proliferation and migration |
| FTF (85) | HIF-1α PI3K/AKT |
angiogenesis |
| Chrysophanol (86) | HIF-1α/VEGF | VEGF, CD31, HIF-1α, HUVECs, MMP-2, MMP-9 |
| Astragaloside IV (87) | AMPK | tumor progress and metastasis |
| Alginic acid (88) | miR-506/STAT3/VEGF-A | STAT3, VEGF-A |
↓: down-regulation.